Oral Tofacitinib in Refractory Pediatric Alopecia Areata

This case series investigates the use of oral tofacitinib in treating refractory pediatric alopecia areata (AA), an autoimmune condition causing hair loss. Seven pediatric patients, aged 2 to 16, with patchy AA unresponsive to conventional therapies, were treated with oral tofacitinib for 1 month. The study found that six out of seven patients experienced significant hair regrowth, with improvements ranging from 50% to 90%, while one patient showed no improvement. No adverse effects were reported during the treatment. The findings suggest that oral tofacitinib could be an effective and safe treatment option for pediatric AA cases that do not respond to standard treatments, although larger studies are necessary to evaluate long-term safety and efficacy.